NCT02386436View on ClinicalTrials.gov

A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 21, 2015

Primary Completion Date

April 11, 2016

Study Completion Date

April 11, 2016

Conditions
Scleroderma, Systemic
Interventions
DRUG

GSK2330811

GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.

DRUG

Placebo

Placebo will be supplied as Normal Saline (0.9% weight by volume \[w/v\] Sodium Chloride) administered as single dose s.c.

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02386436 - A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects | Biotech Hunter | Biotech Hunter